6.57

7.00% 0.43

Pre-market: 6.60 0.03 +0.46%

Verve Therapeutics Inc (VERV)

Overview News Price History Option Chain Financials Why VERV Down? Discussions Forecast

Verve Therapeutics Inc stock is traded at $6.57, with a volume of 2.12M. It is up +7.00% in the last 24 hours and up +14.46% over the past month. Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Previous Close:

$6.14

Open:

$6.25

24h Volume:

2.12M

Relative Volume:

1.44

Market Cap:

$556.24M

Revenue:

$20.65M

Net Income/Loss:

$-192.65M

P/E Ratio:

-2.5367

EPS:

-2.59

Net Cash Flow:

$-134.39M

1W Performance:

+25.14%

1M Performance:

+14.46%

6M Performance:

-4.64%

1Y Performance:

-44.97%

1-Day Range:

$6.145

$6.90

1-Week Range:

$5.315

$6.90

52-Week Range:

$4.305

$19.34

Verve Therapeutics Inc Stock (VERV) Company Profile

Name

Verve Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(978) 501-3026

Address

201 BROOKLINE AVENUE, BOSTON

Employee

255

Twitter

Next Earnings Date

Latest SEC Filings

VERV's Discussions on Twitter

Compare VERV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERV Verve Therapeutics Inc	6.57	556.24M	20.65M	-192.65M	-134.39M	-2.59
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-24	Initiated	H.C. Wainwright	Buy
Apr-13-23	Initiated	Canaccord Genuity	Buy
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral
Dec-15-22	Initiated	Goldman	Sell
Oct-06-22	Initiated	Credit Suisse	Neutral
Aug-25-22	Upgrade	Stifel	Hold → Buy
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Sep-24-21	Initiated	Stifel	Hold
Jul-12-21	Initiated	Guggenheim	Buy
Jul-12-21	Initiated	JP Morgan	Neutral
Jul-12-21	Initiated	Jefferies	Buy
Jul-12-21	Initiated	William Blair	Outperform

View All

Verve Therapeutics Inc Stock (VERV) Latest News

12:36 PM

(VERV) Trading Advice - Stock Traders Daily

12:36 PM

Jan 19, 2025

2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing

Jan 19, 2025

Jan 17, 2025

Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat

Jan 17, 2025

Jan 15, 2025

GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Jan 15, 2025

JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Jan 15, 2025

Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Jan 15, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat

Jan 15, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World

Jan 15, 2025

Jan 14, 2025

Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register

Jan 14, 2025

Jan 13, 2025

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times

Jan 13, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire

Jan 13, 2025

Verve Therapeutics Advances Heart Disease Gene Therapy Pipeline, Extends Cash Runway to 2027 - StockTitan

Jan 13, 2025

Jan 11, 2025

Learn to Evaluate (VERV) using the Charts - Stock Traders Daily

Jan 11, 2025

Jan 09, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire

Jan 09, 2025

Jan 08, 2025

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 08, 2025

Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 08, 2025

Jan 05, 2025